DSGN Design Therapeutics, Inc.

NASDAQ
$9.47

Design Therapeutics, Inc. (DSGN) is expected to report earnings on February 3, 2027, before the market open. The consensus earnings estimate is a loss of $0.55 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.9% since its last earnings release on November 4, 2026.

Design Therapeutics Beat Consensus Estimates
Wednesday, November 4, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · Before Open
Earnings Whisper
-
vs ($0.55)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $10.21

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Design Therapeutics, Inc.

Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.